A novel antibody-drug conjugate targeting SAIL for the treatment of hematologic malignancies

Blood Cancer Journal

Volumn 5, Issue 5, 2015, Pages

  Kim, S Y ^a   Theunissen, J W ^a   Balibalos, J ^a   Liao Chan, S ^a   Babcock, M C ^a   Wong, T ^a   Cairns, B ^b   Gonzalez, D ^b   Van Der Horst, E H ^b   Perez, M ^b   Levashova, Z ^b   Chinn, L ^b   D'Alessio, J A ^a   Flory, M ^a   Bermudez, A ^a   Jackson, D Y ^b   Ha, E ^b   Monteon, J ^b   Bruhns, M F ^b   Chen, G ^a   Migone, T S ^a   more..

^a Igenica Inc   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 67 7A; MONOCLONAL ANTIBODY 7 1C; MONOMETHYL AURISTATIN F; SURFACE ANTIGEN IN LEUKEMIA; TUMOR ANTIGEN; UNCLASSIFIED DRUG; AMINOBENZOIC ACID DERIVATIVE; AURISTATIN; OLIGOPEPTIDE;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG TARGETING; FEMALE; FOLLICULAR LYMPHOMA; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; IN VITRO STUDY; INTERNALIZATION; LARGE CELL LYMPHOMA; MOUSE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PROTEOMICS; TUMOR XENOGRAFT; ANIMAL; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEMATOLOGIC NEOPLASMS; IMMUNOLOGY; IMMUNOTHERAPY; IN SITU HYBRIDIZATION; LIQUID CHROMATOGRAPHY; PROCEDURES; SCID MOUSE; TANDEM MASS SPECTROMETRY; TISSUE MICROARRAY;

AMINOBENZOATES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, LIQUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOTHERAPY; IN SITU HYBRIDIZATION; MICE; MICE, SCID; OLIGOPEPTIDES; TANDEM MASS SPECTROMETRY; TISSUE ARRAY ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84989325782     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2015.39     Document Type: Article

References (36)

1. Lambert JM. Drug-conjugated monoclonal antibodies for the treatment of cancer. Br J Clin Pharmacol 2013; 76: 248-262.
2. Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med 2013; 64: 15-29.
3. Senter PD. Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 2009; 13: 235-244.
4. Leal M, Sapra P, Hurvitz SA, Senter P, Wahl A, Schutten M et al. Antibody-drug conjugates: An emerging modality for the treatment of cancer. Ann N Y Acad Sci 2014; 1321: 41-54.
5. Panowksi S, Bhakta S, Raab H, Polakis P, Junutula JR. Site-specific antibody drug conjugates for cancer therapy. MAbs 2014; 6: 34-45.
6. Beck A, Reichert JM. Antibody-drug conjugates: Present and future. MAbs 2014; 6: 15-17.
7. Mullard A. Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discovery 2013; 12: 329-332.
8. Sassoon I, Blanc V. Antibody-drug conjugate (ADC) clinical pipeline: A review. Methods Mol Biol 2013; 1045: 1-27.
9. Perez HL, Cardarelli PM, Deshpande S, Gangwar S, Schroeder GM, Vite GD et al. Antibody-drug conjugates: Current status and future directions. Drug Discov Today 2014; 19: 869-881.
10. Teicher BA. Antibody-drug conjugate targets. Curr Cancer Drug Targets 2009; 9: 982-1004.
11. Polson AG, Calemine-Fenaux J, Chan P, Chang W, Christensen E, Clark S et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: Target and linker-drug selection. Cancer Res 2009; 69: 2358-2364.
12. Weekes MP, Antrobus R, Lill JR, Duncan LM, Hor S, Lehner PJ. Comparative analysis of techniques to purify plasma membrane proteins. J Biomol Tech 2010; 21: 108-115.
13. Neilson KA, Ali NA, Muralidharan S, Mirzaei M, Mariani M, Assadourian G et al. Less label, more free: Approaches in label-free quantitative mass spectrometry. Proteomics 2011; 11: 535-553.
14. Paoletti AC, Parmely TJ, Tomomori-Sato C, Sato S, Zhu D, Conaway RC et al. Quantitative proteomic analysis of distinct mammalian Mediator complexes using normalized spectral abundance factors. Proc Natl Acad Sci USA 2006; 103: 18928-18933.
15. Zhu W, Smith JW, Huang CM. Mass spectrometry-based label-free quantitative proteomics. J Biomed Biotechnol 2010; 2010: 840518.
16. Sutherland MK, Yu C, Lewis TS, Miyamoto JB, Morris-Tilden CA, Jonas M et al. Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia. MAbs 2009; 1: 481-490.
17. Drake AW, Klakamp SL. A rigorous multiple independent binding site model for determining cell-based equilibrium dissociation constants. J Immunol Methods 2007; 318: 147-152.
18. Liao-Chan S, Daine-Matsuoka B, Heald N, Heald T, Lin T, Cai AG et al. Quantitative assessment of antibody internalization with novel monoclonal antibodies against alexa fluorophores. PLoS One 2015; 10: E0124708.
19. Wang F, Flanagan J, Su N, Wang LC, Bui S, Nielson A et al. RNAscope: A novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn 2012; 14: 22-29.
20. Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity. Bioconjug Chem 2006; 17: 114-124.
21. van der Horst EH, Chinn L, Wang M, Velilla T, Tran H, Madrona Y et al. Discovery of fully human anti-MET monoclonal antibodies with antitumor activity against colon cancer tumor models in vivo. Neoplasia 2009; 11: 355-364.
22. de Sousa Abreu R, Penalva LO, Marcotte EM, Vogel C. Global signatures of protein and mRNA expression levels. Mol Biosyst 2009; 5: 1512-1526.
23. Maier T, Guell M, Serrano L. Correlation of mRNA and protein in complex biological samples. FEBS Lett 2009; 583: 3966-3973.
24. Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J et al. Global quantification of mammalian gene expression control. Nature 2011; 473: 337-342.
25. Bantscheff M, Schirle M, Sweetman G, Rick J, Kuster B. Quantitative mass spectrometry in proteomics: A critical review. Anal Bioanal Chem 2007; 389: 1017-1031.
26. Duncan MW, Aebersold R, Caprioli RM. The pros and cons of peptide-centric proteomics. Nat Biotechnol 2010; 28: 659-664.
27. Ferreras C, Lancrin C, Lie ALM, Kouskoff V, Lacaud G. Identification and characterization of a novel transcriptional target of RUNX1/AML1 at the onset of hematopoietic development. Blood 2011; 118: 594-597.
28. Li D, Poon KA, Yu SF, Dere R, Go M, Lau J et al. DCDT2980S, an anti-CD22- monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma. Mol Cancer Ther 2013; 12: 1255-1265.
29. Recondo G, Diaz Canton E, de la Vega M, Greco M, Recondo G, Valsecchi ME. Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions. World J Clin Oncol 2014; 5: 440-454.
30. Ansell SM, Horwitz SM, Engert A, Khan KD, Lin T, Strair R et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007; 25: 2764-2769.
31. Younes A. CD30-targeted antibody therapy. Curr Opin Oncol 2011; 23: 587-593.
32. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008; 359: 2313-2323.
33. Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol 2014; 11: 12-23.
34. Kung Sutherland MS, Walter RB, Jeffrey SC, Burke PJ, Yu C, Kostner H et al. SGN-CD33A: A novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 2013; 122: 1455-1463.
35. Polson AG, Williams M, Gray AM, Fuji RN, Poon KA, McBride J et al. Anti-CD22- MCC-DM1: An antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma. Leukemia 2010; 24: 1566-1573.
36. Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 2008; 26: 925-932.